Abstract |
An improved NB/70K assay which can be used to reproducibly and accurately measure the NB/70K content of unextracted serum samples has been developed. Analysis of pretreatment serum samples has indicated that the NB/70K assay shows selectivity for ovarian cancer with respect to nonmalignant ovarian cysts and tumors as well as controls; if one considers 10 units of NB/70K as a significant level of antigen, then there are no false positives in the benign and control groups, while 10 of 21 in the ovarian cancer group have significant NB/70K levels. When NB/70K levels of ovarian cancer patients are compared to those of patients with non-ovarian malignant disease, only 4 of 23 patients with non- ovarian cancers had significantly elevated NB/70K levels. However, none of these 4 false positives had levels greater than 20 units.
|
Authors | S Knauf, P Taillon-Miller, B F Helmkamp, T A Bonfiglio, J B Beecham |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 17
Issue 3
Pg. 349-55
(Mar 1984)
ISSN: 0090-8258 [Print] United States |
PMID | 6706232
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Neoplasm
- Immune Sera
|
Topics |
- Animals
- Antigens, Neoplasm
(analysis, immunology)
- Female
- Humans
- Immune Sera
(immunology)
- Ovarian Neoplasms
(immunology)
- Rabbits
(immunology)
- Radioimmunoassay
(methods)
|